Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 7—July 2022
Research

Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021–February 2022

Mircea T. Sofonea, Bénédicte Roquebert, Vincent Foulongne, David Morquin, Laura Verdurme, Sabine Trombert-Paolantoni, Mathilde Roussel, Jean-Christophe Bonetti, Judith Zerah, Stéphanie Haim-Boukobza, and Samuel AlizonComments to Author 
Author affiliations: Université de Montpellier, Montpellier, France (M.T. Sofonea); Laboratoire Cerba, Saint Ouen L’Aumône, France (B. Roquebert, L. Verdurme, S. Trombert-Paolantoni, M. Roussel, S. Haim-Boukobza); Centre Hospitalier Universitaire de Montpellier, Montpellier (V. Foulongne, D. Morquin); Laboratoire Cerballiance Paris et Île-de-France Est, Paris, France (J.-C. Bonetti, J. Zerah); Centre National de la Recherche Scientifique, Paris (S. Alizon)

Main Article

Table 3

Relative risk ratios of covariates associated with SARS-CoV-2 variant-specific screening tests (N = 103,757), France, October 1–December 18, 2021*

Covariate Relative risk ratio (95% CI)
A0B0C0 A0B1C1 A1B0C0 A1B0C1 Other
Intercept
 0 (0.00–0.01)
 0.01 (0–01)
 NS (0–0)
 NS (0–0)
 0.18 (0.17–0.18)
Age, scaled†
 0.85 (0.83–0.88)
 1.08 (1.0–1.2)
 NS (0.7–2.4)
 NS (0.5–1)
 0.82 (0.8–0.83)
Context
General population Referent Referent Referent Referent Referent
Hospital
 NS (0.82–1.1)
 0.37 (0.2–0.69)
 NS —
 NS —
 0.88 (0.79–0.99)
Assay
ID Solutions Referent Referent Referent Referent Referent
PerkinElmer 2.0 (1.8–2.1) 0.46 (0.38–0.56) NS (0–3.8) NS (0.1–1.1) 0.82 (078–0.85)
TIB Molbiol
 2.1 (1.6–2.6)
 10.9 (9–13)
 NS (0.9–23)
 8.3 (3.1–22)
 1.94 (1.8–2.1)
Date and region
Ile-de-France 87.0 (75–100) 4.4 (3.4–5.7) NS (0–7.5) NS (0.3–6.5) 1.7 (1.6–1.8)
Bourgogne-Franche-Comté 10.5 (7.8–14) 8.3 (5.6–12) NS (no values) NS (0–49) 0.63 (0.53–0.74)
Bretagne 37.6 (28–51) NS (0.91–5.4) NS (no values) 21.6 (2–200) 1.3 (1.1–1.6)
Centre-Val de Loire 46.1 (37–57) NA (0.8–3.5) NS (0–370) NS (0–98) NS (0–0)
Corse 86.4 (71–100) 0.2 (0.05–0.5) NS (0–310) NS (0–56) 1.9 (1.7–2.2)
Grand Est 22.2 (18–28) 3.7 (2.3–5.8) NS (0.5–80) NS (0–100) 0.49 (0.42–0.58)
Hauts-de-France 44.8 (38–53) NS (0.4–1.2) NS (0–10) 18.0 (5.5–58) 1.17 (1.10–1.30)
Normandie 38.2 (32–46) 2.2 (1.4–3.4) NS (0–23) NS (0–15) 0.77 (0.69–0.86)
Nouvelle-Aquitaine 17.6 (14–22) 2.7 (1.7–4.4) NS (0–51) NS (0–16) 0.43 (0.37–0.50)
Occitanie 19.8 (16–25) 7.7 (5.3–11) NS (0–95) NS (0–31) NS (0.82–1.1)
Provence-Alpes-Côte d’Azur 19.5 (16–25) NS (0.6–2.2) NS (0–320) NS (0–67) 0.62 (0.54–0.71)
Other 37.6 (26–54) NS (0.6–6.7) NS (no values) NS (no values) NS (0.63–1.10)

*Model only analyzes tests performed after October 25, 2021; tests performed before that date are described in Appendix 1 Table 1. NS, not significant. †Age variable is centered and scaled (1 scaled unit corresponds to 56 years).

Main Article

Page created: May 03, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external